Complicated life, complicated VEGF-B

Trends in Molecular Medicine

Volumn 18, Issue 2, 2012, Pages 119-127

  Li, Xuri ^a   Kumar, Anil ^a   Zhang, Fan ^a   Lee, Chunsik ^a   Tang, Zhongshu ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

Angiogenesis; Apoptosis; Degeneration; Growth factor; Vascular survival; VEGF B

Indexed keywords

RECOMBINANT GROWTH FACTOR; RECOMBINANT VASCULOTROPIN B; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; GROWTH INHIBITION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; REVIEW; STROKE;

ANIMALS; APOPTOSIS; BLOOD VESSELS; GENE EXPRESSION REGULATION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

MUS;

EID: 84856684201     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.11.006     Document Type: Review

References (70)

1. Olofsson B., et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:2576-2581.
2. Grimmond S., et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 1996, 6:124-131.
3. Li X., Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int. J. Biochem. Cell Biol. 2001, 33:421-426.
4. Nash A.D., et al. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm. Pharmacol. Ther. 2006, 19:61-69.
5. Hedlund E.M., et al. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17505-17510.
6. Eriksson A., et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002, 1:99-108.
7. Cao Y., et al. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J. Clin. Invest. 1996, 98:2507-2511.
8. Cao Y., et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J. Biol. Chem. 1996, 271:3154-3162.
9. Li X., et al. Isoform-specific expression of VEGF-B in normal tissues and tumors. Growth Factors 2001, 19:49-59.
10. Aase K., et al. Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. Dev. Dynamics 1999, 215:12-25.
11. Olofsson B., et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:11709-11714.
12. Makinen T., et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J. Biol. Chem. 1999, 274:21217-21222.
13. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2009, 2:re1.
14. Li X., et al. VEGF-B: a survival, or an angiogenic factor?. Cell Adh. Migr. 2009, 3:322-327.
15. Aase K., et al. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 2001, 104:358-364.
16. Bellomo D., et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circulation Res. 2000, 86:E29-E35.
17. Reichelt M., et al. Vascular endothelial growth factor-B and retinal vascular development in the mouse. Clin. Exp. Ophthalmol. 2003, 31:61-65.
18. Louzier V., et al. Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003, 284:L926-L937.
19. Ferrara N., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
20. Carmeliet P., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
21. Karkkainen M.J., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 2004, 5:74-80.
22. Carmeliet P., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
23. Luttun A., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 2002, 8:831-840.
24. Li X., et al. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1614-1620.
25. Mould A.W., et al. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum. 2003, 48:2660-2669.
26. Karpanen T., et al. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ. Res. 2008, 103:1018-1026.
27. Mould A.W., et al. Transgenic overexpression of vascular endothelial growth factor-B isoforms by endothelial cells potentiates postnatal vessel growth in vivo and in vitro. Circ. Res. 2005, 97:e60-e70.
28. Detmar M., et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 1998, 111:1-6.
29. Larcher F., et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998, 17:303-311.
30. Xia Y.P., et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003, 102:161-168.
31. Odorisio T., et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J. Cell Sci. 2002, 115:2559-2567.
32. Jeltsch M., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997, 276:1423-1425.
33. Karkkainen A.M., et al. Vascular endothelial growth factor-D transgenic mice show enhanced blood capillary density, improved postischemic muscle regeneration, and increased susceptibility to tumor formation. Blood 2009, 113:4468-4475.
34. Kiba A., et al. VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem. Biophys. Res. Commun. 2003, 301:371-377.
35. Rissanen T.T., et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 2003, 92:1098-1106.
36. Bhardwaj S., et al. Angiogenic responses of vascular endothelial growth factors in periadventitial tissue. Hum. Gene Ther. 2003, 14:1451-1462.
37. Bhardwaj S., et al. VEGF-A, VEGF-D and VEGF-D induced intimal hyperplasia in carotid arteries. Eur. J. Clin. Invest. 2005, 35:669-676.
38. Sands M., et al. Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung. Respir. Res. 2011, 12:17.
39. Li Y., et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J. Clin. Invest. 2008, 118:913-923.
40. Poesen K., et al. Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. J. Neurosci. 2008, 28:10451-10459.
41. Dvorak H.F., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 1995, 146:1029-1039.
42. Joukov V., et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997, 16:3898-3911.
43. Ogawa S., et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 1998, 273:31273-31282.
44. Brkovic A., Sirois M.G. Vascular permeability induced by VEGF family members in vivo: role of endogenous PAF and NO synthesis. J. Cell Biochem. 2007, 100:727-737.
45. Abraham D., et al. VEGF-A and -C but not -B mediate increased vascular permeability in preserved lung grafts. Transplantation 2002, 73:1703-1706.
46. Zhong X., et al. Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. Mol. Vis. 2011, 17:492-507.
47. Zhang F., et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6152-6157.
48. Claesson-Welsh L. VEGF-B taken to our hearts: specific effect of VEGF-B in myocardial ischemia. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1575-1576.
49. Lahteenvuo J.E., et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 2009, 119:845-856.
50. Sun Y., et al. Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice. J. Cereb. Blood Flow Metab. 2004, 24:1146-1152.
51. Tirziu D., et al. Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J. Clin. Invest. 2007, 117:3188-3197.
52. Shih S.C., et al. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J. Clin. Invest. 2003, 112:50-57.
53. Li X., et al. RNA interference targeting NRP-1 inhibits human glioma cell proliferation and enhances cell apoptosis. Mol. Med. Rep. 2011, 4:1261-1266.
54. Dhondt J., et al. Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons. FASEB J. 2011, 25:1461-1473.
55. Browne S.E., Beal M.F. The energetics of Huntington's disease. Neurochem. Res. 2004, 29:531-546.
56. Hagberg C.E., et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010, 464:917-921.
57. Albrecht I., et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE 2010, 5:e14109.
58. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006, 9:225-230.
59. Jinnin M., et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat. Med. 2008, 14:1236-1246.
60. Shibuya M. Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer. Genes Cancer 2010, 1:1119-1123.
61. Fong G.H., et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
62. Sun Y., et al. Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. Dev. Biol. 2006, 289:329-335.
63. Falk T., et al. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Mol. Neurodegener. 2009, 4:49.
64. Falk T., et al. Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. Neurosci. Lett. 2011, 496:43-47.
65. Eichmann A., et al. Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev. 2005, 19:1013-1021.
66. Hinton D.R., et al. Apoptosis in surgically excised choroidal neovascular membranes in age-related macular degeneration. Archiv. Ophthalmol. 1998, 116:203-209.
67. Kaplan H.J., et al. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat. Med. 1999, 5:292-297.
68. Pons M., Marin-Castano M.E. Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD. Invest. Ophthalmol. Vis. Sci. 2011, 52:3842-3853.
69. Wanstall J.C., et al. Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc. Res. 2002, 55:361-368.
70. Bry M., et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 2010, 122:1725-1733.